Opinion|Videos|January 12, 2024
IsKia: Isatuximab Plus KRd in Pre-Transplant Induction and Post-Transplant Consolidation in TE NDMM
Larry Anderson, MD, goes over the recent data from the IsKia trial which investigated IsaKRd in pre-transplant induction and post-transplant consolidation in TE NDMM.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5